Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 257

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

Efficace, Fabio, Baccarani, Michele, Breccia, Massimo, Alimena, Giuliana, Rosti, Gianantonio, Cottone, Francesco, Deliliers, Giorgio Lambertenghi, Baratè, Claudia, Rossi, Antonella Russo, Fioritoni, Giuseppe, Luciano, Luigia, Turri, Diamante, Martino, Bruno, Di Raimondo, Francesco, Dabusti, Melissa, Bergamaschi, Micaela, Leoni, Pietro, Simula, Maria Pina, Levato, Luciano, Ulisciani, Stefano, Veneri, Dino, Sica, Simona, Rambaldi, Alessandro, Vignetti, Marco, Mandelli, Franco, for GIMEMA · 2011 · Blood

Abstract

The main objective of this study was to investigate whether patients with chronic myeloid leukemia (CML) in treatment with long-term therapy imatinib have a different health-related quality-of-life (HRQOL) profile compared with the general population. In total, 448 CML patients were enrolled, and the SF-36 Health Survey was used to compare generic HRQOL profiles. Symptoms were also assessed. HRQOL comparisons were adjusted for key possible confounders. The median age of patients was 57 years and the median time of imatinib treatment was 5 years (range 3-9 years). The largest HRQOL differences were found in younger patients. In particular, patients aged between 18 and 39 years had marked impairments in role limitations because of physical and emotional problems, respectively: −22.6 (P < .001), −22.3 (P < .001). Patients with CML age 60 or older had a HRQOL profile very similar to that reported by the general population. Women had a worse profile than men when each were compared with their peers in the general population. Fatigue was the most frequently reported symptom. The HRQOL of CML patients is comparable with that of population norms in many areas, however, younger and female patients seem to report the major limitations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-04-347575

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 30 references

Cited by

See all 257

Metadata

Authors
Efficace, F., Baccarani, M., Breccia, M., Alimena, G., Rosti, G., Cottone, F., Deliliers, G. L., Baratè, C., Rossi, A. R., Fioritoni, G., Luciano, L., Turri, D., Martino, B., Di Raimondo, F., Dabusti, M., Bergamaschi, M., Leoni, P., Simula, M. P., Levato, L., Ulisciani, S., Veneri, D., Sica, S., Rambaldi, A., Vignetti, M., Mandelli, F., & GIMEMA, F.
Venue
Blood
Published
2011-10-27
Volume
118
Issue
17
Pages
4554-4560
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2013450609
Cited by
257
References
30
FWCI
9.24
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. https://app.cochat.ai/papers/10.1182/blood-2011-04-347575
The paper
Efficace, F., Baccarani, M., Breccia, M., Alimena, G., Rosti, G., Cottone, F., Deliliers, G. L., Baratè, C., Rossi, A. R., Fioritoni, G., Luciano, L., Turri, D., Martino, B., Di Raimondo, F., Dabusti, M., Bergamaschi, M., Leoni, P., Simula, M. P., Levato, L., . . . GIMEMA, F. (2011). Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. https://doi.org/10.1182/blood-2011-04-347575

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.